Xenon submits Azetukalner NDA to FDA for focal seizures
Xenon announced it submitted an NDA to the FDA for Azetukalner for focal seizures and provided an update on its psychiatry clinical program.
Story updates
08:03:06 PM UTC
SquawkNews
Xenon filed an NDA with the FDA for azetukalner in focal seizures, backed by Phase 2b and Phase 3 data, and temporarily paused new enrollment in MDD/BPD studies to assess neuropsychiatric AEs. Topline X-NOVA2 data are now expected in Q1 2027.Material DetailsContext by AI AnalystThis marks a late-st…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.